Brokerages Set MiNK Therapeutics, Inc. (NASDAQ:INKT) Target Price at $35.00
by Scott Moore · The Cerbat GemMiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) has been assigned a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $35.00.
INKT has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a research note on Wednesday, April 1st. Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th.
Read Our Latest Analysis on MiNK Therapeutics
MiNK Therapeutics Stock Up 2.9%
NASDAQ INKT opened at $11.47 on Friday. The stock has a market cap of $57.01 million, a P/E ratio of -3.86 and a beta of 0.35. The company’s 50-day simple moving average is $10.75 and its 200 day simple moving average is $12.10. MiNK Therapeutics has a twelve month low of $6.34 and a twelve month high of $76.00.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. Research analysts anticipate that MiNK Therapeutics will post -2.75 earnings per share for the current year.
Institutional Trading of MiNK Therapeutics
An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC grew its position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) by 11.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.87% of the company’s stock.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.